The therapeutics of Alzheimer's disease: Where we stand and where we are heading

疾病 医学 认知 临床试验 认知功能衰退 痴呆 阿尔茨海默病 神经炎症 神经科学 纳塔利祖玛 神经影像学 心理学 病理
作者
Dennis J. Selkoe
出处
期刊:Annals of Neurology [Wiley]
卷期号:74 (3): 328-336 被引量:110
标识
DOI:10.1002/ana.24001
摘要

Few diagnoses in modern medicine evoke more apprehension in patients and their families than Alzheimer disease (AD). Defined as a clinical and pathological entity a century ago, the disorder only came under intense molecular scrutiny in the mid‐1980s. Genetic, histopathological, biochemical, and animal modeling studies have combined to provide evidence that the disease may begin with an imbalance between the production and clearance of the self‐aggregating amyloid β protein (Aβ) in brain regions serving memory and cognition. This concept has been furthered by recent analyses in humans of cerebrospinal fluid and neuroimaging biomarkers that suggest an approximate sequence of AD‐type brain alterations beginning >2 decades before the onset of dementia. Although the Aβ hypothesis of Alzheimer causation does not explain all features of this multifactorial syndrome, experimental agents that lower or neutralize Aβ have become the major focus of therapeutic research. Several clinical trials in mild‐to‐moderate AD have not met standard cognitive and functional endpoints, but there were important shortcomings in the agent and/or the trial design in each case. Based on the lessons learned, the field has moved on to test potentially disease‐modifying agents in mild AD patients or via secondary prevention in presymptomatic subjects bearing amyloid plaques. Immunotherapeutic agents are receiving the most study, but other antiamyloid strategies and, importantly, nonamyloid targets such as tau and neuroinflammation are of great interest. The pace of recent developments augurs well for 1 or more experimental agents being shown to slow cognitive decline without major side effects. However, research funding from all sources will need to increase dramatically and soon to stave off the approaching tsunami of AD. Ann Neurol 2013;74:328–336
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
橙子发布了新的文献求助10
1秒前
xx发布了新的文献求助10
1秒前
1秒前
所所的应助被大气的fgyyhjj采纳,获得10
1秒前
xiaot完成签到,获得积分10
1秒前
徐长硕完成签到,获得积分20
1秒前
大模型的应助被故渊丶采纳,获得10
2秒前
2秒前
领导范儿的应助被欢喜若灵采纳,获得10
3秒前
大模型的应助被红雨灰衣采纳,获得10
3秒前
甜美山灵完成签到 ,获得积分10
4秒前
丘比特的应助被纯情的秋天采纳,获得10
4秒前
聪慧雪糕完成签到,获得积分20
4秒前
阳光的山水完成签到 ,获得积分10
4秒前
徐长硕发布了新的文献求助10
5秒前
ping发布了新的文献求助10
5秒前
LuXiaoyu的应助被oleskarabach采纳,获得10
5秒前
疯狂加载ing的应助被oleskarabach采纳,获得10
6秒前
牧百川发布了新的文献求助10
6秒前
7秒前
打打的应助被Felix0917采纳,获得10
7秒前
xiaot发布了新的文献求助10
7秒前
zzz发布了新的文献求助10
7秒前
8秒前
田様的应助被科研小白采纳,获得10
9秒前
tjzbw发布了新的文献求助10
10秒前
10秒前
研二就毕业完成签到,获得积分10
11秒前
晚霞跌落星河的应助被master采纳,获得30
12秒前
4yjmngbfd发布了新的文献求助10
12秒前
星辰大海的应助被稳重的馒头采纳,获得10
13秒前
15秒前
李健的应助被牧百川采纳,获得10
17秒前
风吹麦浪的应助被ping采纳,获得10
18秒前
天青色等烟雨完成签到,获得积分10
18秒前
vbmc发布了新的文献求助30
18秒前
英俊的铭的应助被张会采纳,获得10
18秒前
风吹麦浪的应助被文艺雁兰采纳,获得10
18秒前
Zhangtao完成签到,获得积分0
19秒前
聪慧雪糕发布了新的文献求助10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183621
求助须知:如何正确求助?哪些是违规求助? 9572918
关于积分的说明 21828010
捐赠科研通 7780809
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558243
邀请新用户注册赠送积分活动 2480496